Dual Checkpoint Inhibition in Pancreatic Cancer: Revealing the Limitations of Synergy and the Potential of Novel Combinations
Mené sur 65 patients atteints d’un adénome canalaire du pancréas métastatique (52% d'hommes ; âge médian : 61 ans), cet essai multicentrique randomisé de phase II évalue l’efficacité, du point de vue du taux de réponse objective, et la toxicité du trémélimumab en combinaison avec le durvalumab
Immunotherapy has profoundly altered the treatment landscape in oncology. Immune checkpoint inhibition (ICI) using anti–programmed cell death protein (PD-1) and/or anti–programmed death-ligand 1 (PD-L1) and anti–cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) has led to significant achievements in numerous malignant diseases. Yet, the success of checkpoint inhibition has not translated to every tumor type. With the notable exception of the 1% to 2% of patients with mismatch repair-deficient metastatic pancreatic cancer where anti–PD-1 therapy alone can lead to significant and durable responses, pancreatic ductal adenocarcinoma (PDAC) has remained refractory to single-agent immunotherapy.
JAMA Oncology , commentaire, 2018